Sulodexide and GAGs: Mechanisms and Research Applications
Composition, anticoagulant cofactors, endothelial biology and experimental evidence
Abstract
Sulodexide is a biologically active mixture of sulfated glycosaminoglycans (GAGs), conventionally described as approximately 80% fast-moving heparin (FMH) and 20% dermatan sulfate (DS). This dual composition has motivated investigation of anticoagulant cofactor pathways, endothelial surface biology, inflammatory signaling, extracellular matrix remodeling and the integrity of the endothelial glycocalyx. The mixture cannot be understood simply as interchangeable with unfractionated heparin: its components differ in saccharide sequence, chain distribution, sulfation and interactions with plasma proteins.
This review examines the molecular basis of sulodexide research, compares experimental systems for evaluating component-specific effects, and discusses why preclinical readouts must be interpreted separately from human clinical outcomes. Particular attention is given to the distinction between functional evidence of barrier improvement and direct evidence of glycocalyx structural regeneration.
sulodexide glycosaminoglycans, fast-moving heparin, dermatan sulfate, antithrombin, heparin cofactor II, endothelial glycocalyx, vascular inflammation, GAG research applications
1. What Is Sulodexide?
Sulodexide is a purified, animal-derived mixture of two sulfated polysaccharide fractions, generally obtained from porcine intestinal mucosa. Its defining feature is not a single molecular formula but a specified combination of heparin-related and dermatan sulfate chains. In the literature, fast-moving heparin has also been called an iduronyl glycosaminoglycan sulfate fraction; the terminology derives in part from electrophoretic behavior. It should not be assumed that every sulodexide preparation has identical molecular-weight, sulfate-group or oligosaccharide distributions.
Like other glycosaminoglycans (GAGs), these chains contain acidic sugar residues and varying patterns of sulfation that influence their interactions with proteins. The heparin-related fraction is structurally related to heparan sulfate but is not synonymous with native endothelial heparan sulfate. The dermatan sulfate component belongs to the galactosaminoglycan family, with a backbone different from heparin and heparan sulfate.
Sulodexide has been examined in pharmacological studies of thrombosis, vascular injury and endothelial dysfunction. Some clinical uses are established in certain jurisdictions, but approval status and accepted indications vary by country; findings about clinical efficacy do not prove every proposed cellular mechanism. For bench research, it is more useful to treat sulodexide as a heterogeneous GAG mixture with potentially overlapping physicochemical and biological activities than as a single-target ligand.
Observed antithrombotic, anti-inflammatory or endothelial responses may arise from different components, exposure conditions or downstream events. A change in one biomarker does not uniquely identify its initiating molecular target.
2. Glycosaminoglycan Composition of Sulodexide
Most descriptions of sulodexide report an approximately 80:20 ratio by mass of fast-moving heparin to dermatan sulfate. The ratio describes the bulk formulation, not the abundance of a particular pentasaccharide motif or the fraction of chains that bind a chosen protein. Differences in molecular weight, uronic-acid epimerization, N-sulfation and O-sulfation can all matter in a biological assay.
2.1 Fast-Moving Heparin Fraction
The FMH fraction consists of heparin-like chains containing glucosamine and uronic acid residues. The population is heterogeneous: its individual molecules may differ in length, sequence and distribution of sulfate groups. Antithrombin binding depends on specific oligosaccharide features, rather than on total negative charge alone. When an antithrombin-binding sequence is present, heparin-like molecules can accelerate antithrombin-mediated inhibition of coagulation enzymes. Potent acceleration of thrombin inhibition additionally depends on sufficiently long chains capable of facilitating the appropriate molecular interactions.
Do not equate FMH with a standard low-molecular-weight heparin reference material: electrophoretic classification, size distribution and activity profiles are not identical definitions. Appropriate material characterization can include disaccharide analysis, size distribution and functional anti-factor Xa or anti-factor IIa testing under stated assay conditions.
2.2 Dermatan Sulfate Fraction
Dermatan sulfate is principally built from repeating units of N-acetylgalactosamine and uronic acids, including variable proportions of iduronic acid. Its sulfation pattern—often involving GalNAc 4-O-sulfation and, in some structural domains, additional modifications—affects flexibility and protein recognition. One of its best-studied coagulation-related interactions is with heparin cofactor II (HCII), a serpin that inhibits thrombin.
The activity of DS cannot be predicted exclusively from its share of the mixture. Chain length and local sulfation motifs influence HCII activation, while other biological interactions may be distinct from those of the FMH fraction. Interpreting results from the complete preparation benefits from comparing FMH, DS and the reconstituted mixture at equivalent mass and, where appropriate, equivalent functional activity.
| Characteristic | Fast-Moving Heparin (FMH) | Dermatan Sulfate (DS) |
|---|---|---|
| Typical proportion | Approximately 80% by mass | Approximately 20% by mass |
| Major sugar building blocks | Glucosamine + uronic acids | N-acetylgalactosamine + uronic acids |
| Coagulation-associated pathway | Antithrombin-dependent protease inhibition | HCII-mediated thrombin inhibition |
| Key structure variables | Chain length, N-/O-sulfation, AT-binding motifs | Iduronic acid content, sulfation and sequence domains |
| Analytical caution | Not automatically equivalent to a standard LMWH | Not interchangeable with chondroitin sulfate |
Figure 1. Conceptual composition of sulodexide. The approximately 80:20 mass ratio does not specify a single chain sequence or molecular size.
3. Interactions with Antithrombin and Heparin Cofactor II
Sulodexide provides a useful case study in how mixtures of structurally distinct GAGs can affect the coagulation network through different serpin pathways. Antithrombin (AT) and HCII are both inhibitors of coagulation enzymes, but their relevant GAG interactions and substrate preferences should not be conflated.
3.1 Antithrombin-dependent pathways
Antithrombin inhibits activated coagulation proteases, including factor Xa and thrombin. Certain heparin-like oligosaccharides bind antithrombin and accelerate inhibitory activity by inducing a conformational change and, in sufficiently long chains, facilitating template-like encounters. For research assays, anti-Xa and anti-IIa readouts reflect not just the mass concentration of a GAG but also the availability of antithrombin, molecular size distribution and method-specific calibration.
3.2 Heparin cofactor II-dependent pathways
HCII is particularly relevant to DS-associated enhancement of thrombin inhibition. Dermatan sulfate binding may accelerate formation of the HCII–thrombin inhibitory complex. Experimental testing should account for HCII concentration, thrombin dose, sample matrix and sulfation patterns; an activity increase is not proof that only DS contributes to the overall effect of a complete mixture.
3.3 How to disentangle the mechanisms
To evaluate the mechanism, use matched samples with and without purified AT or HCII, or carefully controlled plasma-based systems that selectively address these cofactors. Compare functional assays with independent composition characterization. Anti-Xa activity, anti-IIa activity, thrombin-generation parameters and clotting times answer different questions and should not be treated as equivalent surrogate endpoints. One study directly compared sulodexide, its components and heparin using multiple coagulation assays, illustrating how protocol choice alters apparent activity.
| Experimental question | Possible method | Interpretation limitation |
|---|---|---|
| AT-dependent factor Xa inhibition? | Chromogenic anti-Xa assay with defined AT conditions | Activity depends on standards and cofactor availability |
| HCII-dependent thrombin inhibition? | Purified HCII/thrombin kinetics with and without DS | Other plasma inhibitors complicate bulk plasma assays |
| Net effect on coagulation? | Thrombin-generation assay and selected clotting tests | Plasma composition and analytical reagents matter |
| Which structures drive activity? | Fraction comparison plus size and disaccharide profiling | Disaccharide totals do not reconstruct sequence motifs |
4. Sulodexide in Vascular and Endothelial Research
The endothelial surface presents an organized glycocalyx made of proteoglycans, glycoproteins, hyaluronan and sulfated GAG chains. This dynamic layer influences permeability, circulating-cell contact, mechanotransduction and the availability of signaling molecules. Because sulodexide supplies heparin-like and DS chains, researchers have investigated whether exposure can alter glycocalyx degradation, endothelial repair and vascular responses.
In a rat carotid balloon-injury model, investigators reported changes consistent with improved glycocalyx appearance, accompanied by altered endothelial nitric oxide synthase (eNOS) expression, inflammatory adhesion markers and vascular remodeling. These observations provide a mechanistic hypothesis—not a guarantee that the administered mixture directly incorporates into the endothelial layer or that the same response will occur in other organs.
Endothelial effects can be assessed using cultured microvascular or macrovascular endothelial cells under static conditions or physiologically relevant shear stress. Models exposed to high glucose, inflammatory stimuli or oxidative injury can help test whether sulodexide modifies glycocalyx-associated outcomes. However, immortalized cells, primary endothelial cells and three-dimensional microvascular constructs may display very different baseline glycocalyx architectures.
It is useful to distinguish three potential explanations of a measured improvement: reduced shedding of existing GAG structures, altered biosynthesis or remodeling of the layer, and changes in barrier function that occur without demonstrable glycocalyx growth. Measurements at multiple time points and with orthogonal techniques are needed to tell these apart.
5. Investigating Inflammation and Glycocalyx-Related Mechanisms
Inflammatory environments may accelerate endothelial glycocalyx loss through regulated shedding, protease activity, glycocalyx-degrading enzymes and changes to GAG synthesis. Such changes can influence leukocyte access to adhesion molecules, chemokine presentation and permeability. Because glycosaminoglycans can interact with multiple positively charged proteins, sulodexide may affect inflammatory readouts through mechanisms beyond classical coagulation inhibition.
Proposed routes include modulation of heparanase-associated degradation, changes in protease-dependent remodeling, and altered cytokine or adhesion-related signaling. These are candidate pathways whose strength of evidence depends on the model. Reduced syndecan-1 release, for example, can be compatible with decreased shedding, but it does not alone demonstrate reconstruction of an intact surface glycocalyx. Likewise, reduced ICAM-1 or VCAM-1 expression shows altered endothelial activation rather than direct proof of a particular GAG–protein binding event.
In vitro studies might compare sulodexide against FMH and DS individually under TNF-α challenge, measuring adhesion-molecule expression, leukocyte binding, heparanase activity and GAG abundance. A stronger approach incorporates a rescue or blocking strategy, such as selective enzymatic degradation of HS-rich structures, while acknowledging that such enzymes may alter both baseline biology and the treatment response.
Figure 2. Conceptual experimental framework for separating glycocalyx structure, shedding biomarkers and functional barrier changes after sulodexide exposure.
6. Preclinical Research Models and Experimental Approaches
Model selection determines which aspects of sulodexide biology can be credibly investigated. Cell systems offer controlled perturbations but often lack circulating proteins and true vascular hemodynamics. Animal injury models permit integrated tissue responses yet introduce species differences in coagulation and GAG metabolism. Human observational and interventional research provides clinical relevance but rarely permits direct molecular attribution.
| Study platform | Useful experimental endpoints | Strengths and limitations |
|---|---|---|
| Purified biochemical system | AT/HCII kinetics, factor Xa/thrombin inhibition, size and sulfation profiling | Strong control of reactants; omits cellular and plasma complexity |
| Endothelial cell culture | HS staining, syndecan shedding, TEER or tracer permeability, adhesion markers | Mechanistic perturbation possible; glycocalyx often differs from in vivo tissue |
| Microfluidic vascular models | Shear-dependent barrier behavior, leukocyte adhesion, surface staining | Flow is tunable; device materials and culture conditions influence results |
| Animal vascular injury models | Histology, ultrastructure, glycocalyx appearance, remodeling and inflammation | Whole-organism context; translation and direct mechanism remain uncertain |
| Human translational studies | Vascular biomarkers, permeability-associated endpoints, clinical outcomes | Relevant to patients; difficult to assign effects to a specific GAG fraction |
6.1 Experimental controls and material characterization
Use a vehicle control, independent positive control appropriate to the endpoint, dose-response series and time-course measurements. If the aim is to link an effect to one component, compare the whole mixture with qualified FMH and DS fractions and an explicitly described reconstituted mixture. A standard heparin comparator may provide mechanistic context but should not be described as a compositionally matched control.
Document material origin, batch, purity, residual contaminants, molecular size distribution and, when available, sulfate or disaccharide profiles. Mass-based dose equivalence alone does not ensure equal active-site concentrations. For inflammation assays, endotoxin testing matters because low-level contamination could distort cell activation readouts. For fluorescence imaging, antibody specificity, fixation-induced changes and accessibility of charged GAG structures must also be controlled.
6.2 Measuring endothelial glycocalyx integrity
No single method is sufficient. Lectin or antibody imaging can map selected epitopes but may not measure total glycocalyx thickness. Electron microscopy provides structural detail yet is sensitive to preparation and fixation artifacts. Shed syndecan-1, heparan sulfate fragments or hyaluronan in fluid samples can reflect release from diverse tissue sources. Functional assays—such as tracer permeability, transendothelial electrical resistance or leukocyte adhesion—can establish physiological effects but are not glycocalyx-specific. The strongest evidence combines morphology, chemistry and a functional endpoint.
6.3 Translating exposure between platforms
In vitro concentrations are not directly interchangeable with oral or parenteral dosing schedules in vivo. Uptake, plasma binding, clearance, route of administration and tissue access may alter effective exposure. Preclinical researchers should report the actual treatment schedule and sampled compartment rather than relying on a presumed equivalence between nominal dose and endothelial exposure.
7. Research Limitations and Unanswered Questions
Structural heterogeneity. Because sulodexide contains distributions of different chains, mechanistic claims cannot be reduced to a single precise structural epitope without additional fractionation and sequencing evidence. Product-to-product and lot-to-lot analytical consistency should be reported.
Component-specific attribution. Interactions with AT and HCII are established biological pathways, but inflammatory and endothelial responses may be indirect or shared among fractions. Studies comparing whole sulodexide to one unrelated GAG are insufficient to assign causality to a particular component.
Direct glycocalyx restoration. Improved permeability or reduced circulating shedding markers does not necessarily demonstrate that a lost endothelial glycocalyx has physically regrown. Whether the predominant mechanism is enzymatic protection, altered synthesis, replacement of surface constituents or a downstream anti-inflammatory effect remains context-dependent.
Model and vascular-bed variability. Glycocalyx organization differs across large arteries, microvessels and specific organs. Reported human vascular-bed differences after sulodexide exposure underscore why one anatomical location cannot be assumed to represent all vessels.
Clinical interpretation. Clinical studies in vascular disorders can inform relevance and safety but should not be used to retroactively validate an untested cellular explanation. Indications, regulatory status, comparative benefit and bleeding-related assessments also vary by country and clinical setting.
Priority research questions. Which sulfation or size features associate with endothelial effects? Can direct surface incorporation be differentiated from reduced degradation? Which observations persist under physiological shear flow? Are the most informative assays sensitive enough to distinguish vascular-bed-specific behavior? Better fraction-level characterization and orthogonal causal measurements will help answer these questions.
Sulodexide and other GAG materials are valuable research tools because their heterogeneous chains span several protein-interaction pathways. Strong mechanistic studies integrate precise material identity, cofactor-dependent functional tests, glycocalyx imaging and biologically relevant controls rather than inferring one molecular mechanism from a broad phenotypic improvement.
References
- Ofosu FA. Pharmacological actions of sulodexide. Semin Thromb Hemost. 1998;24(2):127–138. doi:10.1055/s-2007-995831.
- Carroll BJ, Piazza G, Goldhaber SZ. Sulodexide in venous disease. J Thromb Haemost. 2019. doi:10.1111/jth.14324.
- Hoppensteadt DA, Fareed J. Comparative anticoagulant and thrombin generation inhibitory profile of heparin, sulodexide and its components. Int J Mol Sci. 2020. Full text.
- Li T, et al. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Oncotarget. 2017. Full text.
- Brogani P, et al. The glycocalyx and its role in vascular physiology and vascular related diseases. Front Cell Dev Biol. 2020. Review.
- Gouverneur M, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010. Full text.
- Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2014;8:49–65. Full text.